WINT
Windtree Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 90.0K | — | — | — | — |
| Cost of Revenue | 412.0K | 84.0K | 82.0K | 1.1M | 869.0K |
| Gross Profit | (349.0K) | (84.0K) | (82.0K) | (1.1M) | (869.0K) |
| Operating Expenses | |||||
| R&D Expense | 8.5M | 16.3M | 8.3M | 11.1M | 17.8M |
| SG&A Expense | 7.7M | 8.7M | 9.2M | 10.8M | 14.5M |
| General & Admin Expense | 7.7M | 8.7M | 8.7K | 10.8M | 14.5M |
| Selling & Marketing Expense | — | — | 9.2M | — | — |
| Other Expenses | 17.3M | (84.0K) | 3.1M | (1.5M) | (869.0K) |
| Total Operating Expenses | 33.5M | 24.9M | 17.5M | 20.4M | 31.4M |
| Cost and Expenses | 33.5M | 25.0M | 17.5M | 21.5M | 32.3M |
| Operating Income (EBIT) | (33.5M) | (25.0M) | (17.5M) | (41.3M) | (77.3M) |
| Non-Operating | |||||
| Interest Income | 971.0K | 70.0K | 325.0K | 109.0K | 91.0K |
| Interest Expense | 488.0K | 235.0K | 50.0K | 53.0K | 114.0K |
| Net Interest Income | 483.0K | (165.0K) | 275.0K | 56.0K | (23.0K) |
| Other Non-Op Income/Expense | (10.0M) | 23.2M | (2.8M) | 758.0K | (45.4M) |
| Non-Operating Income (excl Interest) | 9.5M | (23.5M) | 2.7M | (19.8M) | 229.0K |
| EBT (Pre-Tax Income) | (43.5M) | (1.8M) | (20.3M) | (40.6M) | (77.6M) |
| Income Tax Expense | (3.5M) | 3.7M | — | (1.4M) | (10.0M) |
| Bottom Line | |||||
| Net Income | (40.0M) | (5.5M) | (20.3M) | (39.2M) | (67.6M) |
| Earnings from Cont. Ops | (40.0M) | (5.5M) | (20.3M) | (39.2M) | (67.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (48.8M) | (5.5M) | (20.3M) | (39.2M) | (67.6M) |
| Per Share | |||||
| Basic EPS | ($8.50) | ($104.35) | ($4,711.54) | ($56,011.00) | ($122,924.00) |
| Diluted EPS | ($8.50) | ($104.35) | ($4,711.54) | ($56,011.00) | ($122,924.00) |
| Revenue Per Share | $3.37 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 26675 | 52583 | 4306 | 700 | 550 |
| Diluted Shares Outstanding | 26675 | 52583 | 4306 | 700 | 550 |
| Profitability Metrics | |||||
| EBITDA | (42.6M) | (1.5M) | (20.2M) | (39.5M) | (76.6M) |
| D&A | 412.0K | 84.0K | 82.0K | 1.1M | 869.0K |
| EBIT | (43.0M) | (1.6M) | (20.2M) | (40.5M) | (77.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025